Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

380.10DKK
4:01am EDT
Change (% chg)

kr.2.20 (+0.58%)
Prev Close
kr.377.90
Open
kr.378.90
Day's High
kr.380.60
Day's Low
kr.377.60
Volume
222,041
Avg. Vol
2,326,008
52-wk High
kr.415.00
52-wk Low
kr.305.10

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 1.22
Market Cap(Mil.): kr.760,346.69
Shares Outstanding(Mil.): 2,012.56
Dividend: 6.40
Yield (%): 1.69

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 28.12 35.76 36.62
EPS (TTM): 13.43 -- --
ROI: 89.73 15.33 14.52
ROE: 99.26 16.37 15.68

Lilly sales beat estimates, helped by newer drugs

Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade due to its growing roster of medicines.

Jul 26 2016

UPDATE 3-Lilly sales beat estimates, helped by newer drugs

July 26 Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade due to its growing roster of medicines.

Jul 26 2016

Novo Nordisk invests $60 mln to expand insulin plant in Kalundborg

* Danish pharmaceutical company Novo Nordisk is investing 400 million Danish crowns ($59.70 million) in a 500 square meter extension of the world's largest insulin production plant in Kalundborg, it said on Monday.

Jul 04 2016

Swiss stocks - Factors to watch on June 28

ZURICH, June 28 The Swiss blue-chip SMI was seen opening 1.1 percent higher at 7,676 points on Tuesday, according to premarket indications by bank Julius Baer .

Jun 28 2016

BRIEF-Ypsomed Holding collaborates with Novo Nordisk

* Collaborates with Novo Nordisk to provide new solutions in insulin pump therapy Source text: http://bit.ly/293IVRQ Further company coverage: (Gdynia Newsroom)

Jun 28 2016

BRIEF-Novo A/S, main owner of Novo Nordisk, appoints Kasim Kutay as new CEO

* Says appoints Kasim Kutay as new CEO from September 1, 2016

Jun 21 2016

Novo diabetes drug cuts heart risks by less-than-hoped 13 percentage

Novo Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study, but the result disappointed investors who had hoped for more.

Jun 14 2016

UPDATE 2-Novo diabetes drug cuts heart risks by less-than-hoped 13 pct

* Investors had hoped for bigger benefit, shares off 5 pct (Adds further reaction, latest shares)

Jun 14 2016

BRIEF-Novo Nordisk reports positive results from semaglutide trial

* Says semaglutide demonstrated superior improvements in glycaemic control vs rivals sitagliptin and exenatide ER in two clinical trials in adults with type 2 diabetes

Jun 12 2016

U.S. panel backs approval of Sanofi combination diabetes drug

One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

May 25 2016

Earnings vs. Estimates